Cytokinetics Inc (NAS:CYTK)
$ 48.08 -0.9 (-1.84%) Market Cap: 5.04 Bil Enterprise Value: 5.28 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc To Host Virtual Investor & Analyst Day Transcript

Oct 19, 2023 / 12:30PM GMT
Release Date Price: $32.81 (-4.34%)
Diane Weiser
Cytokinetics, Incorporated - SVP of Corporate Communications & IR

Good morning. I'm Diane Weiser, Senior Vice President, Corporate Communications and Investor Relations. I'm pleased to welcome you to new horizons and hypercontractility. Our 2023 Virtual Investor and Analyst Day. Over the course of the next few hours, we plan to review the broad development program for Aficamten and outline commercial readiness for its potential approval and launch in obstructive hypertrophic cardiomyopathy as well as present new preclinical data for CK-586, a cardiac myosin inhibitor in development for the potential treatment of patients with heart failure with preserved ejection fraction.

Today's slides are available for download on the right side of the webcast. We will be hosting a Q&A session at the end of our program today. (Operator Instructions) Next slide.

Before I continue, please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot